N-BOC-4-乙氧基哌啶 | 460367-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-BOC-4-乙氧基哌啶
• 英文名称: tert-butyl 4-ethoxypiperidine-1-carboxylate
• 英文别名: 4-ethoxy-piperidine-1-carboxylic acid tert-butyl ester
• CAS: 460367-82-2
• 化学式: C₁₂H₂₃NO₃
• 分子量: 229.32
• InChiKey: HBVGRSULKDLDRU-UHFFFAOYSA-N

物化性质

• 沸点：
  291.7±33.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 4-ethoxypiperidine-1-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-ethoxypiperidine-1-carboxylate
CAS number: 460367-82-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H23NO3
Molecular weight: 229.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-BOC-4-乙氧基哌啶 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以0.500 g的产率得到4-乙氧基哌啶
  参考文献：
  名称：

  [EN] ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
  [FR] COMPOSÉS DE TYPE ALCYNE EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHIONE RÉDUCTASE

  摘要：

  提供的是式(Ia)的化合物及其药学上可接受的盐，其中A、B、R1、R2、m和n如本文所定义，这些化合物作为S-硝基谷胱甘肽还原酶(GSNOR)的抑制剂具有活性。这些化合物可以预防、抑制或抑制GSNOR的作用，因此在治疗GSNOR介导的疾病、疾病、综合征或病症方面具有用处，例如肺动脉高压、急性呼吸窘迫综合征(ARDS)、哮喘、支气管痉挛、咳嗽、肺炎、肺纤维化、间质性肺疾病、囊性纤维化和慢性阻塞性肺疾病(COPD)。

  公开号：

  WO2016055947A1
• 作为产物：
  描述：

  碘乙烷 、 N-Boc-4-羟基哌啶 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以2.2 g的产率得到N-BOC-4-乙氧基哌啶
  参考文献：
  名称：

  AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

  摘要：

  一种用于抑制蛋白酪氨酸激酶活性的氨基嘧啶化合物，其制药组合物、制备方法及应用。具体来说，一种由式（I）表示的氨基嘧啶化合物，其中规范中定义了R1、R2、L、Y、R6、W、A、m和n，以及其药用可接受的盐、立体异构体、溶剂化合物、水合物、多形性、前药或同位素变体。该化合物可用于治疗和/或预防蛋白酪氨酸激酶相关疾病，如细胞增殖性疾病、癌症和免疫性疾病。

  公开号：

  US20190152954A1

文献信息

• [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078454A1

  公开（公告）日：2014-05-22

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式I的化合物：或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C和X如本文定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。
• Compound
  申请人：Toda Ayako

  公开号：US20050261177A1

  公开（公告）日：2005-11-24

  This invention relates to new polypeptide compound represented by the following general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

  本发明涉及一种由以下一般式（I）表示的新多肽化合物：其中R1、R2、R3、R4、R5和R6如描述中所定义或其盐，具有抗微生物活性（特别是抗真菌活性），抑制β-1,3-葡聚糖合酶的活性，制备其的方法，包含其的药物组合物，以及用于预防和/或治疗包括肺孢子虫感染（例如肺孢子虫肺炎）在内的人类或动物的传染病的方法。
• Aza-benzofuranyl compounds and methods of use
  申请人：Savy Pierre Pascal

  公开号：US20080085886A1

  公开（公告）日：2008-04-10

  The invention relates to azabenzofuranyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗癌和/或抗炎活性的Formula I的氮杂苯并呋喃化合物，更具体地涉及抑制MEK激酶活性的氮杂苯并呋喃化合物。本发明提供了用于抑制异常细胞生长或治疗哺乳动物的增生性疾病或治疗炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Chroman compounds
  申请人：Bernstein Peter

  公开号：US20070135442A1

  公开（公告）日：2007-06-14

  Compounds according to Formula (I) below: wherein R 1 , R 2 , R 3 , and R 4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

  根据下面的公式（I）合成化合物： 其中R1、R2、R3和R4如规范中定义，药学上可接受的盐，制备方法，含有该化合物的制药组合物以及使用该化合物的方法。